- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 00:01 | XFRA NEW INSTRUMENTS AVAILABLE ON XETRA - 05.11.2024 | 86 | Xetra Newsboard | The following instruments on XETRA do have their first trading 05.11.2024 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 05.11.2024
Aktien
1 CA13740E1079 Cancambria Energy Corp.
2... ► Artikel lesen | |
| 04.10. | Cytophage Technologies Ltd.: Cytophage CEO to Discuss Reshaping Healthcare Through Phage Therapies During 2024 Canada SynBio Conference | 1 | TheNewswire | ||
| 29.08. | Cytophage Technologies Ltd: Cytophage's June 30 cash at $3.65-million | 1 | Stockwatch | ||
| 28.08. | Cytophage Technologies reports Q2 results | 1 | Seeking Alpha | ||
| 28.08. | Cytophage Technologies Ltd.: Cytophage Reports Q2 Financials including Business Update for First Half of 2024 | 1 | TheNewswire | ||
| 15.08. | Cytophage Technologies Ltd: Cytophage rolls out lyophilized tablets for poultry | 1 | Stockwatch | ||
| 15.08. | Cytophage Develops Freeze-Dried Phage Tablets For Poultry | 1 | The Deep Dive | ||
| 15.08. | Phage Therapy's Rising Demand: Cytophage at the Forefront with Dr. Steven Theriault | 1 | The Deep Dive | ||
| 15.08. | Cytophage Technologies Ltd.: Cytophage Launches Ready-to-Use Lyophilized Phage Tablets to Improve Gut Health in Poultry | 1 | TheNewswire | ||
| 27.06. | Cytophage Technologies Ltd: Cytophage holders approve all matters at AGM | 1 | Stockwatch | ||
| 27.06. | Cytophage Technologies Ltd.: Cytophage Reports AGM Results and Announces Upcoming Investor Call | 1 | TheNewswire | ||
| 21.06. | Cytophage Enters Letter Of Intent With Major Singapore-Based Agrifood Company | 1 | The Deep Dive | ||
| 20.06. | Cytophage Technologies Ltd: Cytophage to conduct trials with Asian poultry co. Q4 | 1 | Stockwatch | ||
| 20.06. | Cytophage Technologies Ltd.: Cytophage Expands Commercialization of Phage Products in Asian Poultry Market | 1 | TheNewswire | ||
| 04.06. | Cytophage Technologies Ltd.: Cytophage CEO to Present at TEDx Winnipeg Event | 1 | TheNewswire | ||
| 30.05. | Cytophage Technologies Ltd: Cytophage's March 31 cash at $5.56-million | 1 | Stockwatch | ||
| 30.05. | Cytophage Technologies Ltd.: Cytophage Reports Q1 Financials and Provides Business Update | 1 | TheNewswire | ||
| 27.05. | Cytophage Technologies Ltd: Cytophage Technologies appoints Snisarenko as director | 1 | Stockwatch | ||
| 27.05. | Cytophage Adds 30-Year Biotech Exec To Its Board | 1 | The Deep Dive | ||
| 27.05. | Cytophage Technologies Ltd.: Cytophage Strengthens Board of Directors | 1 | TheNewswire |
20 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 8,190 | +1,11 % | EQS-News: Evotec SE: Bekanntgabe der Ergebnisse für die ersten neun Monate 2024 am 06. November 2024 | EQS-News: Evotec SE
/ Schlagwort(e): Sonstiges
Evotec SE: Bekanntgabe der Ergebnisse für die ersten neun Monate 2024 am 06. November 2024
30.10.2024 / 08:10 CET/CEST
Für... ► Artikel lesen | |
| ADMA BIOLOGICS | 19,120 | 0,00 % | ADMA Biologics, Inc. (NASDAQ:ADMA) Holdings Increased by Roman Butler Fullerton & Co. | ||
| DISC MEDICINE | 58,19 | 0,00 % | Disc Medicine Inc: Disc Medicine Announces Successful End of Phase 2 Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria (EPP), Including Potential for Accelerated Approval | Alignment with the FDA across all proposed study parameters, providing a clear development path to registrationAgreement on proposed primary endpoint of average monthly time in sunlight during the... ► Artikel lesen | |
| QIAGEN | 40,310 | +0,35 % | QIAGEN N.V.: QIAGEN erhält FDA-Zulassung für QIAstat-Dx Mini-Panel für eine präzisere ambulante Behandlung von Atemwegserkrankungen | QIAstat-Dx Respiratory Panel Mini erkennt die fünf relevantesten Erreger von Atemwegserkrankungen im ambulanten Bereich und hilft Ärzten dabei, präzise Behandlungsentscheidungen zu treffen // Mithilfe... ► Artikel lesen | |
| LONGBOARD PHARMACEUTICALS | 59,52 | 0,00 % | Longboard Pharmaceuticals, Inc.: Lundbeck to Acquire Longboard Pharmaceuticals in a Strategic Deal, Significantly Enhancing Its Neuroscience Pipeline | The proposed acquisition represents a significant step forward in Lundbeck's Focused Innovator strategy, adding a highly innovative and complementary product in late-stage development for Developmental... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 44,820 | 0,00 % | Avidity Biosciences target held at $59 by Goldman Sachs | ||
| SUMMIT THERAPEUTICS | 19,980 | 0,00 % | Summit Therapeutics Reports Operational Progress and Financial Results for the Third Quarter and Nine Months Ended September 30, 2024 | MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reported an update on its operational progress and financial results for the third quarter... ► Artikel lesen | |
| VIKING THERAPEUTICS | 58,00 | -0,10 % | Nach Kursvervierfachung: Viking Therapeutics: "Großartiger" Test bei Adipositas-Pille - Aktie explodiert! | Die Aktie von Viking Therapeutics haussiert am Montag um 26 Prozent, nachdem eine klinische Studie mit seiner experimentellen oralen Gewichtsabnahmepille vielversprechende Ergebnisse gezeigt hat.Eine... ► Artikel lesen | |
| HARMONY BIOSCIENCES | 33,075 | 0,00 % | Harmony Biosciences Reports Strong Third Quarter 2024 Financial Results And Highlights Catalyst-rich, Late-stage Pipeline Poised To Deliver One Or More New Launches Every Year Over Next Five Years | WAKIX (pitolisant) Net Revenue of $186.0 Million for Third Quarter 2024; Surpassed $2B in Cumulative Net Revenue in Less Than Five Years
On Track to Submit sNDA... ► Artikel lesen | |
| ARCELLX | 86,46 | 0,00 % | Arcellx (ACLX) Surged in Q3. Here's Why | ||
| BEAM THERAPEUTICS | 24,340 | 0,00 % | Beam Therapeutics Reports Third Quarter 2024 Financial Results and Progress Across Priority Programs | ||
| DYNE THERAPEUTICS | 28,780 | 0,00 % | Dyne Therapeutics Reports Positive Data From Phase 1/2 DELIVER Trial Of DYNE-251 In DMD | WASHINGTON (dpa-AFX) - Tuesday, Dyne Therapeutics, Inc. (DYN) revealed new clinical findings from its Phase 1/2 DELIVER trial of DYNE-251 for patients with Duchenne muscular dystrophy also known... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 6,620 | 0,00 % | Peering Into Recursion Pharmaceuticals' Recent Short Interest | ||
| IMMUNOVANT | 29,435 | 0,00 % | Immunovant Inc.: Immunovant Announces Oral Presentation of Late Breaking Abstract for Phase 2 Graves' Disease Clinical Data at the 2024 American Thyroid Association (ATA) Annual Meeting | ||
| TARSUS PHARMACEUTICALS | 46,240 | 0,00 % | Tarsus Pharmaceuticals stock hits 52-week high at $42.63 |
Das Unternehmen CYTOPHAGE TECHNOLOGIES LTD kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,164 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CYTOPHAGE TECHNOLOGIES LTD finden Sie auf Wallstreet Online.
